SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GREG FINLEY who wrote (274)7/23/1998 7:39:00 PM
From: Marc Kahn  Read Replies (1) of 534
 
I "attended" a conference call this morning with Bioject and GeneMedicine. I noted the following points which you folks may find of interest:

On Merck:
- Upfront payment from Merck to Bioject of $1.5M to enter into discussions.
- Intent is for collaboration on a group of certain vaccines.
- Discussions have already begun, with Merck's people having been at Bioject's offices this week.

- No immediate revenue from the GeneMedicine deal, but the potential for licensing fees from other parties already involved with GMED.

- Any new products with GMED will be new drugs which will require FDA approval. More than a year to market.

- The intradermal device referred to in the press release, as being in front of the FDA, is a variation of the Biojector 2000, modified to spread medicine into the skin.

- Impressive inroads have been made in marketing the Biojector system to the US military.

- Bioject is continuing to seek out and talk to other companies about potential alliances.

- Q1 earnings report will be out within 2 weeks.

- New York City is considering expanding their Biojector vaccine program from only hepatitis B to other vaccines.

- The Hoffman-LaRoche device is in front of the FDA on a 510K. Once approved, that will help sales figures.

Hope this helps,
Marc Kahn
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News